Torben Bjerregaard Larsen1, Lars Hvilsted Rasmussen2, Anders Gorst-Rasmussen3, Flemming Skjøth3, Deirdre A Lane4, Gregory Y H Lip5. 1. Department of Cardiology, Aalborg Atrial Fibrillation Study Group, Aalborg University Hospital, Aalborg, Denmark; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark. Electronic address: tobl@rn.dk. 2. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark. 3. Department of Cardiology, Aalborg Atrial Fibrillation Study Group, Aalborg University Hospital, Aalborg, Denmark; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark. 4. University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK. 5. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark; University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Abstract
BACKGROUND: This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillation patients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin. METHODS: We identified, in nationwide Danish registries, 2398 patients with atrial fibrillation and a history of stroke/transient ischemic attack, making a first-time purchase of dabigatran 110 mg twice a day (bid; D110) and 150 mg bid (D150). Patients were categorized as either vitamin K antagonist (VKA) naive or experienced. Warfarin controls were identified using a complete (for VKA-naive dabigatran patients) or matched sampling approach (for VKA-experienced dabigatran patients). Subjects were followed for an average of 12.6 months for stroke and transient ischemic attacks. Confounder-adjusted Cox regression models were used to compare event rates between treatments. RESULTS: Among patients with a history of stroke/transient ischemic attack and prior VKA experience, switching to dabigatran was associated with an increased stroke/transient ischemic attack rate for both dabigatran doses compared with continuing on warfarin (D110 hazard ratio [HR] 1.99; 95% confidence interval [CI], 1.42-2.78; D150 HR 2.34; 95% CI, 1.60-3.41). Among prior stroke/transient ischemic attack patients who were new starters on dabigatran or warfarin, the rate of stroke/transient ischemic attack for both doses of dabigatran was similar to or lower than warfarin (D110 HR 0.64; 95% CI, 0.50-0.80; D150 HR 0.92l; 95% CI, 0.73-1.15). CONCLUSIONS: In this register-based study, VKA-experienced patients with a history of stroke or transient ischemic attack who switched to dabigatran therapy had an increased rate of stroke compared with patients persisting with warfarin therapy.
BACKGROUND: This register-based observational study compares dabigatran to warfarin for secondary stroke prevention in atrial fibrillationpatients among both "new starters" on dabigatran and "switchers" to dabigatran from warfarin. METHODS: We identified, in nationwide Danish registries, 2398 patients with atrial fibrillation and a history of stroke/transient ischemic attack, making a first-time purchase of dabigatran 110 mg twice a day (bid; D110) and 150 mg bid (D150). Patients were categorized as either vitamin K antagonist (VKA) naive or experienced. Warfarin controls were identified using a complete (for VKA-naive dabigatranpatients) or matched sampling approach (for VKA-experienced dabigatranpatients). Subjects were followed for an average of 12.6 months for stroke and transient ischemic attacks. Confounder-adjusted Cox regression models were used to compare event rates between treatments. RESULTS: Among patients with a history of stroke/transient ischemic attack and prior VKA experience, switching to dabigatran was associated with an increased stroke/transient ischemic attack rate for both dabigatran doses compared with continuing on warfarin (D110 hazard ratio [HR] 1.99; 95% confidence interval [CI], 1.42-2.78; D150 HR 2.34; 95% CI, 1.60-3.41). Among prior stroke/transient ischemic attack patients who were new starters on dabigatran or warfarin, the rate of stroke/transient ischemic attack for both doses of dabigatran was similar to or lower than warfarin (D110 HR 0.64; 95% CI, 0.50-0.80; D150 HR 0.92l; 95% CI, 0.73-1.15). CONCLUSIONS: In this register-based study, VKA-experienced patients with a history of stroke or transient ischemic attack who switched to dabigatran therapy had an increased rate of stroke compared with patients persisting with warfarin therapy.
Authors: Leo M Stolk; Frank de Vries; Chiel Ebbelaar; Anthonius de Boer; Tom Schalekamp; Patrick Souverein; Arina Ten Cate-Hoek; Andrea M Burden Journal: Br J Clin Pharmacol Date: 2017-03-23 Impact factor: 4.335
Authors: Anne Holbrook; Colin Dormuth; Richard Morrow; Agnes Lee; Sue Troyan; Guowei Li; Eleanor Pullenyegum Journal: BMJ Open Date: 2016-11-24 Impact factor: 2.692
Authors: Gaisa T Kairov; Maksim A Solovev; Larisa Y Kotlovskaya; Vladimir V Udut Journal: Clin Appl Thromb Hemost Date: 2018-11-28 Impact factor: 2.389